Inner Mongolia Furui Med Sci - Asset Resilience Ratio
Inner Mongolia Furui Med Sci (300049) has an Asset Resilience Ratio of 2.43% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Inner Mongolia Furui Med Sci (300049) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how Inner Mongolia Furui Med Sci's Asset Resilience Ratio has changed over time. See Inner Mongolia Furui Med Sci (300049) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Inner Mongolia Furui Med Sci's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300049 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥83.62 Million | 2.43% |
| Total Liquid Assets | CN¥83.62 Million | 2.43% |
Asset Resilience Insights
- Limited Liquidity: Inner Mongolia Furui Med Sci maintains only 2.43% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Inner Mongolia Furui Med Sci Industry Peers by Asset Resilience Ratio
Compare Inner Mongolia Furui Med Sci's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Inner Mongolia Furui Med Sci (2010–2025)
The table below shows the annual Asset Resilience Ratio data for Inner Mongolia Furui Med Sci.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.43% | CN¥83.62 Million ≈ $12.24 Million |
CN¥3.44 Billion ≈ $503.22 Million |
-2.72pp |
| 2024-12-31 | 5.15% | CN¥157.50 Million ≈ $23.05 Million |
CN¥3.06 Billion ≈ $447.61 Million |
+1.59pp |
| 2023-12-31 | 3.55% | CN¥94.11 Million ≈ $13.77 Million |
CN¥2.65 Billion ≈ $387.41 Million |
-1.84pp |
| 2022-12-31 | 5.40% | CN¥136.20 Million ≈ $19.93 Million |
CN¥2.52 Billion ≈ $369.21 Million |
-0.38pp |
| 2021-12-31 | 5.78% | CN¥145.80 Million ≈ $21.34 Million |
CN¥2.52 Billion ≈ $369.43 Million |
+3.68pp |
| 2020-12-31 | 2.10% | CN¥48.00 Million ≈ $7.02 Million |
CN¥2.29 Billion ≈ $335.18 Million |
-3.95pp |
| 2019-12-31 | 6.05% | CN¥136.10 Million ≈ $19.92 Million |
CN¥2.25 Billion ≈ $329.28 Million |
+1.52pp |
| 2018-12-31 | 4.53% | CN¥96.68 Million ≈ $14.15 Million |
CN¥2.14 Billion ≈ $312.62 Million |
-2.19pp |
| 2017-12-31 | 6.72% | CN¥168.62 Million ≈ $24.67 Million |
CN¥2.51 Billion ≈ $367.37 Million |
+2.24pp |
| 2016-12-31 | 4.48% | CN¥107.80 Million ≈ $15.77 Million |
CN¥2.41 Billion ≈ $352.17 Million |
+0.22pp |
| 2015-12-31 | 4.26% | CN¥87.00 Million ≈ $12.73 Million |
CN¥2.04 Billion ≈ $298.65 Million |
+7.67pp |
| 2014-12-31 | -3.41% | CN¥-45.40 Million ≈ $-6.64 Million |
CN¥1.33 Billion ≈ $194.80 Million |
+0.12pp |
| 2013-12-31 | -3.53% | CN¥-40.29 Million ≈ $-5.90 Million |
CN¥1.14 Billion ≈ $167.08 Million |
-59.95pp |
| 2010-12-31 | 56.42% | CN¥448.91 Million ≈ $65.69 Million |
CN¥795.66 Million ≈ $116.43 Million |
-- |
About Inner Mongolia Furui Med Sci
Inner Mongolia Furui Medical Science Co., Ltd. engages in the production and sale of pharmaceutical drugs in China and internationally. The company operates in two segments: pharmaceutical production and sales; and diagnostic equipment R&D, production and sales. The pharmaceutical production and sales segment produces and sells products, such as Fufang Biejiaruangan tablets and shell fat capsules… Read more